BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mori S. Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis. Clin Med Insights Circ Respir Pulm Med 2015;9:41-9. [PMID: 26401101 DOI: 10.4137/CCRPM.S23288] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Zhang C. Flare-up of cytokines in rheumatoid arthritis and their role in triggering depression: Shared common function and their possible applications in treatment (Review). Biomed Rep 2021;14:16. [PMID: 33269077 DOI: 10.3892/br.2020.1392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Wu EK, Ambrosini RD, Kottmann RM, Ritchlin CT, Schwarz EM, Rahimi H. Reinterpreting Evidence of Rheumatoid Arthritis-Associated Interstitial Lung Disease to Understand Etiology. Curr Rheumatol Rev 2019;15:277-89. [PMID: 30652645 DOI: 10.2174/1573397115666190116102451] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
3 Geerts S, Wuyts W, Langhe E, Lenaerts J, Yserbyt J. Connective tissue disease associated interstitial pneumonia: a challenge for both rheumatologists and pulmonologists. Sarcoidosis Vasc Diffuse Lung Dis 2017;34:326-35. [PMID: 32476865 DOI: 10.36141/svdld.v34i4.5894] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Mori S, Furukawa H, Kawaguchi Y, Suda T, Tasaka S. Current Developments in Interstitial Lung Disease. Clin Med Insights Circ Respir Pulm Med 2015;9:173-7. [PMID: 27656093 DOI: 10.4137/CCRPM.S40867] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Wang Y, Song W, Wu J, Li Z, Mu F, Li Y, Huang H, Zhu W, Zhang F. Modeling using clinical examination indicators predicts interstitial lung disease among patients with rheumatoid arthritis. PeerJ 2017;5:e3021. [PMID: 28243535 DOI: 10.7717/peerj.3021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
6 Kalinova D, Kolarov Z, Rashkov R. Organising pneumonia - the first manifestation of rheumatoid arthritis. Reumatologia 2017;55:314-7. [PMID: 29491540 DOI: 10.5114/reum.2017.72629] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
7 Wu EK, Henkes ZI, McGowan B, Bell RD, Velez MJ, Livingstone AM, Ritchlin CT, Schwarz EM, Rahimi H. TNF-Induced Interstitial Lung Disease in a Murine Arthritis Model: Accumulation of Activated Monocytes, Conventional Dendritic Cells, and CD21+/CD23- B Cell Follicles Is Prevented with Anti-TNF Therapy. J Immunol 2019;203:2837-49. [PMID: 31659014 DOI: 10.4049/jimmunol.1900473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
8 Wang J, Zhao Q. Expression of CCR3, SOX5 and LC3 in patients with elderly onset rheumatoid arthritis and the clinical significance. Exp Ther Med 2017;14:3573-6. [PMID: 29042950 DOI: 10.3892/etm.2017.4961] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
9 Das S, Padhan P. An Overview of the Extraarticular Involvement in Rheumatoid Arthritis and its Management. J Pharmacol Pharmacother 2017;8:81-6. [PMID: 29081614 DOI: 10.4103/jpp.JPP_194_16] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
10 Mori S, Ogata F, Tsunoda R. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review. Clin Rheumatol 2021;40:4457-71. [PMID: 34554329 DOI: 10.1007/s10067-021-05911-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ataman S, Sunar I, Bodur H, Melikoglu MA, Cay HF, Capkin E, Akgul O, Cevik R, Gogus F, Kamanli A, Yurdakul FG, Gurer G, Yagci I, Rezvani A, Duruoz MT. Demographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis. Rheumatol Ther 2021. [PMID: 34850376 DOI: 10.1007/s40744-021-00403-y] [Reference Citation Analysis]